Bluejay Diagnostics, Inc.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
On April 8, 2025, pursuant to the April 7, 2025 Inducement Letter Agreements with certain existing holders of the Company’s Class C Warrants, the Company sold 1,085,106 Class E Warrants to purchase unregistered shares of Common Stock for an immediate payment of $0.125 per Class E Warrant. Each Class E Warrant has an exercise price of $3.42 per share and expires on April 8, 2030. The sales proceeds were used for general corporate purposes.
Pursuant to the Inducement Letter Agreements, the Company agreed to file a registration statement providing for the resale by the purchasers of the shares of Common Stock issuable upon exercise of the Class E Warrants. On April 29, 2025, the Company filed Form S-3 with the Securities and Exchange Commission to register the sale of common stock issuable to the selling stockholders upon exercise of the Class E Warrants.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.